Artaç M.Pehlivan S.Akcan S.Pehlivan M.Gelen T.Itirli G.Aksoy N.Özdogan M.Savaş B.Samur M.Bozcuk H.2019-10-262019-10-2620081019-31031019-3103https://hdl.handle.net/11454/21152The aim of our study was to assess the relationship between microsatellite instability (MSI) and the clinical outcome in metastatic colorectal cancer (CRC) patients treated with irinotecan-based regimens. We assessed best objective response, progression free survival (PFS) and overall survival (OAS) in relation to MSI analysis that was performed using BAT-25, BAT-26, D5S346, D2S123, D17S250 markers in normal and tumor DNA. The best objective response was significantly and negatively related with the D17S250 (an adjacent locus to p53) microsatellite marker (p=0.047). However, MSI score was not related with the best objective response (p=0.88). There was again no relationship between PFS, OAS and MSI score. In conclusion, this study allowed us to establish in a prospective study design that MSI status did not predict survival in metastatic colorectal cancer patients treated with irinotecan-based regimens.eninfo:eu-repo/semantics/closedAccessColon cancerIrinotecanMicrosatellite instabilityPCRArticle3824956N/A